KRTX - Karuna Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
104.52
+8.78 (+9.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close95.74
Open95.36
Bid103.62 x 800
Ask108.50 x 1000
Day's Range92.71 - 105.42
52 Week Range11.24 - 152.00
Volume1,091,057
Avg. Volume801,904
Market Cap2.719B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est118.67
  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Jan. 10

    Insiders invest in Salesforce.com, Lamb Weston, Karuna Therapeutics and Compass Diversified Holdings Continue reading...

  • Business Wire

    Karuna Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. The Company is scheduled to present on Thursday, January 16, 2020, at 11:00 a.m. PT.

  • The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK
    Zacks

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

  • 5 Best Performing IPOs of 2019
    Zacks

    5 Best Performing IPOs of 2019

    This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

  • Year’s Best U.S. IPO Is a Little-Known Biotech With 420% Surge
    Bloomberg

    Year’s Best U.S. IPO Is a Little-Known Biotech With 420% Surge

    (Bloomberg) -- Karuna Therapeutics Inc. may not be the year’s best-known initial public offering, taking a back seat to names like Beyond Meat Inc. and Uber Technologies Inc. But for those on the hunt for generous returns, early bets on the mid-cap drugmaker paid off handsomely.Thanks to some positive study results in November, Karuna is 2019’s best-performing U.S. IPO. Early Karuna holders saw more than 420% returns since the June IPO at $16 a share, and next week a handful of the biotech’s top holders will get a chance to reap the rewards when they get the first chance to sell.Puretech Health Plc, a co-inventor of Karuna’s lead program, is the largest holder with a 28% stake, according to Bloomberg data, and will be able to sell shares after the 180-day restriction expires on Dec. 25. The next largest holder, Fidelity Management & Research Co. with a 15% stake, will also get that chance. The investment firm added to its stake in September ahead of the medical trial readout.“Karuna is positioned to be a major new player in a field that (while very lucrative) has been lacking innovation for decades,” Daphne Zohar, Puretech’s chief executive, said via email, referring to the area of brain diseases, which has been riddled with failures. She declined to comment on future plans for the stake in Karuna.The rally on results from Karuna’s lead therapy, KarXT for psychotic symptoms in schizophrenia, led the drug developer to break tradition and do a secondary offering before the lockup expired. Goldman Sachs Inc. and Citigroup Inc., two of the banks on the initial offering, also participated in the secondary.That offering priced at $96 a share. The stock has come down from a November peak when shares rose as high as $152 on an intraday basis to trade in the $85 range. But Wall Street analysts -- including those on the recent offerings -- remain undaunted with all six covering analysts having buy ratings. The average price target forecasts another rise of about 40% for the stock.Under the secondary, insiders and top holders with ties to Karuna’s board, like Arch Capital and Sofinnova Ventures, are now subject to new selling restrictions, which won’t expire until late February.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jim Silver, Cécile DauratFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Is Karuna Therapeutics, Inc. (KRTX) A Good Stock To Buy ?
    Insider Monkey

    Is Karuna Therapeutics, Inc. (KRTX) A Good Stock To Buy ?

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • Karuna Therapeutics Shares March Higher, Can It Continue?
    Zacks

    Karuna Therapeutics Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Karuna Therapeutics

  • Business Wire

    Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY. Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide.

  • Business Wire

    Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the pricing of its previously announced underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million. The offering is expected to close on November 25, 2019, subject to customary closing conditions.

  • Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
    Zacks

    Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

    Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

  • Here's Why This Biotech Stock Has Septupled In Value Over Two Days
    Investor's Business Daily

    Here's Why This Biotech Stock Has Septupled In Value Over Two Days

    Karuna stock has nearly septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test. The drug proved itself over five weeks.

  • Company News For Nov 19, 2019
    Zacks

    Company News For Nov 19, 2019

    Companies in the news are: KRTX, EROS, CARO, SNNA

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • Dow Jones Futures: Can Software Rejoin Stock Market Rally? Apple Event Planned; These Stocks Are Moving On News
    Investor's Business Daily

    Dow Jones Futures: Can Software Rejoin Stock Market Rally? Apple Event Planned; These Stocks Are Moving On News

    Stock futures: Can software rejoin the market rally as Paylocity breaks out? ServiceNow added to gains late. Apple, Karuna Therapeutics, Roku and ZTO Express moved on news too.

  • Business Wire

    Karuna Therapeutics Announces Proposed Public Offering of Common Stock

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock. Karuna intends to grant the underwriters a 30-day option to purchase an additional 390,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size and terms of the offering.

  • MarketWatch

    Karuna Therapeutics' stock more than triples after upbeat trial results of schizophrenia treatment

    Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial of its schizophrenia treatment met its primary endpoint. Trading volume ballooned to 6.5 million shares, compared with the full-day average of about 70,000 shares. The company said its KarXT port the treatment of acute psychosis in schizophrenia patients demonstrated a "statistically significant and clinically meaningful" reduction in total positive and negative syndrome scale (PANSS) score compared with a placebo. KarXT was also well tolerated. "With this information, and following our anticipated end-of-Phase 2 meeting with the FDA in the second quarter of 2020, we will work to initiate a Phase 3 clinical trial of KarXT in patients with schizophrenia by the end of 2020," said Chief Medical Officer Stephen Brannan. The stock, which went public on June 28 at an initial-public-offering price of $16, has nearly tripled (up 182%) over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 5.5% and the S&P 500 has rallied 7.9%.

  • Business Wire

    Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. In the clinical trial, KarXT demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative Syndrome Scale (PANSS) score compared to placebo (p

  • Business Wire

    Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced it will hold a webcast and conference call on Monday, November 18, 2019 at 8:30 a.m. EST to provide results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. The dial-in numbers are 1-855-548-1216 for domestic callers and 1-409-216-6318 for international callers. A live webcast of the conference call will also be available on the investor relations page of the Karuna Therapeutics corporate website at www.karunatx.com.

  • Business Wire

    Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update

    BOSTON-- -- Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in Alzheimer’s disease and pain on track to commence by the end of 2019 Cash, cash equivalents and short-term investment balance of $161.6 million to fund development of novel ...

  • GuruFocus.com

    Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares

    President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.